Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
which has seen a handful of FDA approvals starting with the CellSearch CTC system in 2013 and followed by additional diagnostics from Roche and Grail. The overall liquid biopsy market is expected ...
Equipment available: MagPix (Luminex Corporation, Austin, TX) system features an innovative design based on CCD fluorescent imaging technology. MagPix is a versatile multiplexing platform capable of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback